Since a significant relation between high Fn14 expression and poor tumor prognosis has been previously reported in gliomas [35] and with a recent study supporting the therapeutic potential of Fn14-specific bispecific Ab and CAR-T/IL-15 cells against GBM [40], Fn14 appears as a potential target for CAR-based immunotherapies. This evidence concerns the gene TNFRSF12A and glioblastoma.